

**Remarks**

Applicants have cancelled claims 1-11, 15-22, 35-40 and 50-56 and withdrawn claims 34, 41-49. Claims 12, 13 and 14 have also been amended. Support for the claim amendments is found throughout the specification, specifically at page 7 Table 1. Claims 23-27, 30, 34 and withdrawn claims 41 and 45 have further been amended to appropriately reflect the claim dependency. Applicants have also added new claims 57-60. Claims 57-58 read upon the elected claims comprising the CDRs of original claim 12 and the variable region sequences of original claim 11. Basis for the newly added claim 59 and 60 can be found throughout the specification, specifically on page 13, column 1, last paragraph for Claim 59 and page 11, column 2, first full paragraph.

Applicants submit that these amendments add no new matter. Reconsideration of the present application in view of the amendments and remarks presented herein is respectfully requested.

Respectfully submitted,

/Sanjay M. Jivraj/  
Sanjay M. Jivraj  
Attorney for Applicants  
Registration No. 61,806  
Phone: 317-433-3495

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

May 28, 2009